title: Serum sclerostin levels following treatment with parathyroid hormone.
authors: S A
authors: SA
authors: Polyzos
authors: A D
authors: AD
authors: Anastasilakis
authors: E
authors: E
authors: Terpos
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000097:blood*; D010281:Parathyroid Hormone / Q000097:blood*; D017698:Postmenopause
chemical_list: D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D010281:Parathyroid Hormone; D019386:Alendronate
references: Osteoporos Int. 2012 Mar;23(3):1171-6
references: 21305266
references: J Endocrinol Invest. 2012 Oct;35(9):866-8
references: 22842667
references: J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62
references: 20631014
references: J Clin Endocrinol Metab. 2011 Nov;96(11):E1848-51
references: 21865370
references: Calcif Tissue Int. 2010 Nov;87(5):398-405
references: 20838781
references: Bone. 2012 Mar;50(3):739-42
references: 22178539
references: Osteoporos Int. 2013 Feb;24(2):489-94
references: 22525978
references: J Clin Endocrinol Metab. 2011 May;96(5):1555-9
references: 21367927